H. pylori, Peptic Ulcers, and Gastritis

Most people who develop peptic ulcers or chronic stomach inflammation can trace it back to a single bacterial culprit: Helicobacter pylori. This corkscrew-shaped bacterium has lived in the human stomach for at least 100,000 years, but its role in causing ulcers was only confirmed in 1983 — a discovery that overturned decades of medical dogma and eventually earned Barry Marshall and Robin Warren the Nobel Prize. Today we know that H. pylori accounts for roughly 80–95% of all duodenal ulcers and about 70% of gastric ulcers. Understanding exactly how it does this damage — and what that damage feels like — is the first step toward getting the right diagnosis and treatment.

The Urease Enzyme: H. pylori's Acid Shield
CagA Virulence Factor: The Toxin That Drives Ulcers
Gastric Ulcers vs. Duodenal Ulcers
Chronic Active Gastritis: Inflammation Stages
MALT Lymphoma: A Rare but Serious Complication
Upper GI Bleeding: When to Seek Emergency Care
NSAIDs and H. pylori: A Doubly Dangerous Combination
After Eradication: What Happens to Ulcers
Key Research Papers
Connections
Featured Videos

The Urease Enzyme: H. pylori's Acid Shield

The stomach produces hydrochloric acid at a pH between 1.5 and 3 — acidic enough to dissolve metal. No bacterium should survive there. H. pylori manages the trick by producing an enzyme called urease in extraordinary amounts. Urease splits urea (a natural byproduct of protein metabolism that diffuses into the stomach from the blood) into ammonia and carbon dioxide. Ammonia is a base, and it neutralizes acid right around the bacteria, creating a tiny alkaline microenvironment that shields H. pylori from destruction.

This ammonia cloud is not just a passive shield — it is actively toxic to the stomach lining. Ammonia disrupts the mucus layer that normally protects the stomach wall from its own acid. Once that mucus barrier is thinned or breached, gastric acid can reach the underlying epithelial cells, triggering inflammation and, over time, erosions and ulcers. The urease test — a rapid, inexpensive lab test performed on a biopsy sample during endoscopy — exploits exactly this enzyme to confirm an H. pylori infection within minutes.

Urease also plays a key role in the urea breath test, one of the most accurate non-invasive ways to diagnose active H. pylori infection. You swallow a capsule of labeled urea; if H. pylori is present, its urease breaks the urea down and the labeled carbon appears in your exhaled breath, detectable by a simple analyzer. A positive breath test means the bacteria are active and producing urease right now.

CagA Virulence Factor: The Toxin That Drives Ulcers and Cancer Risk

Not all H. pylori strains are equally dangerous. About 60–70% of strains in Western countries — and up to 90% of strains in some parts of East Asia — carry a gene called cagA (cytotoxin-associated gene A). Strains that carry this gene are called cagA-positive, and they cause significantly more severe disease than cagA-negative strains.

The cagA gene is part of a larger structure called the cag pathogenicity island — a cluster of about 30 bacterial genes that encode a molecular syringe known as a type IV secretion system. This syringe physically injects the CagA protein directly into human stomach cells. Once inside, CagA hijacks normal cell signaling pathways: it mimics growth factors, disrupts the proteins that hold cells together (tight junctions), triggers chronic inflammation, and pushes cells toward abnormal division. It is, in effect, a bacterial oncogene delivered via infection.

People infected with cagA-positive H. pylori have a higher risk of peptic ulcers and a significantly higher risk of gastric adenocarcinoma — the most common type of stomach cancer — compared to people infected with cagA-negative strains. This is why H. pylori is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). It does not mean everyone with cagA-positive H. pylori will develop cancer; the vast majority will not. But the risk is real enough that eradication is recommended for all infected individuals regardless of symptoms.

A second important virulence factor is VacA (vacuolating cytotoxin A), a toxin secreted by H. pylori that punches holes in cell membranes, triggering the formation of large vacuoles inside gastric cells and inducing cell death. Different VacA subtypes vary in potency, and the most aggressive combinations of cagA and VacA are associated with the highest ulcer and cancer rates.

Gastric Ulcers vs. Duodenal Ulcers: Two Different Patterns

A peptic ulcer is an open sore in the lining of the stomach or the upper portion of the small intestine (the duodenum). H. pylori causes the majority of both types, but the underlying mechanism differs, and that difference matters for how the ulcer feels.

Duodenal ulcers are the most common type and are almost always caused by H. pylori — the bacterium is responsible for 80–95% of all duodenal ulcers. H. pylori infection in the stomach's antrum (the lower portion) triggers excess production of gastrin, a hormone that signals the stomach to make more acid. That extra acid floods into the duodenum, overwhelming its bicarbonate defenses and eroding the lining. Duodenal ulcer pain typically peaks 2–3 hours after eating, when the stomach has emptied but acid secretion is still elevated. Many people find that eating actually relieves the pain temporarily, because food buffers the acid. Night pain — waking at 1–3 a.m. with a gnawing or burning sensation in the upper abdomen — is a classic duodenal ulcer pattern.

Gastric ulcers behave differently. H. pylori colonizes the body and antrum of the stomach, damaging the mucus layer and allowing acid to attack the stomach wall from inside. Because the ulcer is in the stomach itself, eating can actually worsen the pain — food stimulates acid secretion right onto the sore. Gastric ulcer pain often peaks during or shortly after meals. Weight loss is more common with gastric ulcers because people begin to avoid eating due to pain.

Both types cause a burning, gnawing, or dull ache in the upper-middle abdomen (epigastrium). The pain can radiate to the back. Some people have almost no pain until a complication develops — bleeding, perforation, or obstruction — which is why H. pylori can cause damage silently for years.

Chronic Active Gastritis: Inflammation Stages and What They Feel Like

Before ulcers develop, H. pylori almost always causes gastritis — inflammation of the stomach lining. Nearly every person infected with H. pylori has some degree of gastritis, though many feel nothing at all. The inflammatory process follows a predictable sequence that can span decades.

Acute gastritis occurs right after initial infection. The immune system mounts an attack, flooding the stomach lining with neutrophils (white blood cells). This can cause a brief illness with nausea, vomiting, and upper abdominal pain. Most people don't realize this is H. pylori; they chalk it up to a stomach bug. The acute phase resolves, but the bacteria remain, and the immune response never fully clears them.

Chronic active gastritis is the persistent low-grade inflammatory state that follows. The stomach lining is continuously infiltrated by lymphocytes, plasma cells, and intermittent neutrophils. At this stage, symptoms may be absent or vague: occasional bloating, mild upper-abdominal discomfort after meals, burping, early satiety (feeling full quickly). Many people live with this for years without seeking medical attention.

Atrophic gastritis is a more advanced stage in which the normal acid-secreting glands of the stomach are gradually destroyed and replaced by fibrous tissue or intestinal-type cells. Acid production drops — which sounds like a relief, but it actually removes an important barrier against other infections and bacteria in food. Atrophic gastritis significantly raises the risk of gastric cancer, particularly when it involves the body (corpus) of the stomach rather than just the antrum.

Intestinal metaplasia is the final pre-cancerous stage: the stomach lining starts to resemble intestinal tissue. This is not cancer, but it is a warning sign that careful monitoring is warranted, especially in people over 50 with a long history of H. pylori infection.

Many people with chronic gastritis describe their symptoms as "just always feeling off" — a persistent sense of fullness, mild nausea, or discomfort they have normalized over years. Dyspepsia (indigestion) that doesn't respond to antacids should always prompt testing for H. pylori.

MALT Lymphoma: A Rare but Serious Complication

One of the more remarkable consequences of H. pylori infection is its link to a type of stomach cancer called MALT lymphoma (mucosa-associated lymphoid tissue lymphoma). Normally, the stomach contains no lymphoid tissue — the immune cells that form lymphomas. H. pylori infection triggers the stomach to develop lymphoid follicles as part of the chronic immune response. In rare cases, these abnormal lymphoid accumulations undergo malignant transformation, becoming a low-grade B-cell lymphoma.

MALT lymphoma is uncommon — it affects about 1 in 30,000 people with H. pylori infection — but it has a striking feature that sets it apart from most cancers: in 60–80% of cases, eradicating H. pylori with antibiotics causes the lymphoma to go into complete remission without chemotherapy or radiation. This makes H. pylori-driven MALT lymphoma one of the only human cancers that can be cured with antibiotics alone.

Symptoms of MALT lymphoma are often identical to chronic gastritis: vague upper abdominal discomfort, nausea, and early satiety. It is typically discovered during endoscopy performed for other reasons. If your doctor finds MALT lymphoma and also detects H. pylori, eradication is the first-line treatment. Most patients are monitored with repeat endoscopies every few months to confirm regression.

Higher-grade MALT lymphomas — those that have accumulated additional genetic mutations and are no longer dependent on H. pylori signaling — do require standard lymphoma treatment. This is another reason why prompt detection and eradication of H. pylori matters: catching MALT lymphoma early, while it is still H. pylori-dependent and low-grade, dramatically improves outcomes.

Upper GI Bleeding: When to Seek Emergency Care

Peptic ulcers bleed when the erosion reaches a blood vessel in the stomach or duodenal wall. Upper gastrointestinal bleeding is a medical emergency that kills approximately 1 in 20 affected patients. Recognizing the warning signs can save your life.

Vomiting blood — whether bright red (indicating active, brisk bleeding) or dark brown/coffee-ground material (indicating blood that has sat in stomach acid long enough to be partially digested) — requires an immediate emergency room visit. Do not wait to see if it resolves.

Black, tarry stools (melena) occur when blood from the upper digestive tract passes through the intestines and is chemically altered into a dark, sticky, foul-smelling stool. Even a relatively small bleed can produce melena. If your stools are black and tarry and you have not taken iron supplements or bismuth (Pepto-Bismol makes stools black), go to the emergency room.

Dizziness, rapid heart rate, fainting, or feeling very weak alongside abdominal pain or the symptoms above suggest significant blood loss. These are signs of hemodynamic instability — your body is struggling to maintain blood pressure — and require immediate care.

Sudden, severe abdominal pain that spreads across the entire abdomen and makes the abdomen rigid and board-like may indicate a perforation — the ulcer has eaten completely through the stomach or duodenum wall. Perforation is a surgical emergency with a mortality rate that rises sharply with every hour of delay.

Most upper GI bleeds from peptic ulcers are treated with endoscopy, which allows the doctor to inject medication or apply clips or heat directly to the bleeding vessel. After the acute bleed is controlled, eradicating H. pylori dramatically reduces the risk of re-bleeding — studies show that rebleeding rates drop from about 30% to under 5% after successful eradication.

NSAIDs and H. pylori: A Doubly Dangerous Combination

Non-steroidal anti-inflammatory drugs (NSAIDs) — ibuprofen (Advil, Motrin), naproxen (Aleve), aspirin, and prescription NSAIDs like diclofenac — are the second leading cause of peptic ulcers after H. pylori. When someone has both H. pylori infection and regular NSAID use, the combined ulcer risk is far greater than either factor alone — roughly multiplicative rather than additive.

NSAIDs damage the stomach lining through two mechanisms. First, they inhibit the COX-1 enzyme, which normally signals the stomach to produce its protective prostaglandins. Prostaglandins stimulate mucus secretion, bicarbonate production, and blood flow to the stomach wall — all of which defend the lining against acid. When COX-1 is blocked, these defenses drop. Second, NSAIDs are weakly acidic compounds that can directly damage gastric cells on contact.

H. pylori already depletes the mucus layer through its urease-produced ammonia and its virulence factors. Adding NSAIDs to an H. pylori-infected stomach is like removing the remaining fire protection from an already-smoldering building. Population studies consistently show that people with both H. pylori and regular NSAID use have ulcer complication rates 3–4 times higher than those with only one risk factor.

The practical implication: if you need long-term NSAIDs for arthritis or cardiovascular disease and you have known or suspected H. pylori infection, your doctor should test for and eradicate H. pylori before starting or continuing NSAID therapy. If you need NSAIDs urgently before eradication is complete, a proton pump inhibitor (PPI) like omeprazole should be co-prescribed to reduce acid and give the stomach lining partial protection. Low-dose aspirin taken for cardiovascular prevention is often unavoidable; in those patients, H. pylori testing is especially important.

After Eradication: What Happens to Ulcers

Here is the good news that most people with H. pylori don't fully appreciate: eradicating H. pylori with a course of antibiotics heals the vast majority of peptic ulcers permanently and prevents them from coming back. This is fundamentally different from treating ulcers with antacids or acid-suppressing drugs alone, which relieve pain and promote temporary healing but leave the underlying infection — and thus the underlying damage mechanism — in place.

With antacid therapy alone, duodenal ulcers recur in about 70–80% of patients within one year. After successful H. pylori eradication, the recurrence rate drops to under 5% at one year and remains low indefinitely, as long as reinfection does not occur. The stomach lining, freed from the constant bacterial attack, has a remarkable capacity to heal. Even atrophic gastritis — the thinning of stomach glands that develops after years of infection — can partially reverse after eradication, particularly in younger patients and those who are treated before intestinal metaplasia has developed.

Most uncomplicated duodenal ulcers heal within 4–8 weeks of eradication therapy. Gastric ulcers typically take 8–12 weeks. Your doctor will usually prescribe a proton pump inhibitor alongside the antibiotics during triple or quadruple therapy, and may continue the PPI for several weeks afterward to keep acid suppressed while the ulcer heals. A follow-up urea breath test or stool antigen test 4–8 weeks after completing antibiotics confirms that eradication was successful.

A small minority of ulcers do not heal after eradication — these are sometimes called refractory ulcers. Causes include antibiotic resistance leading to treatment failure, undetected NSAID use, a rare acid-secreting tumor called a gastrinoma (Zollinger-Ellison syndrome), or Crohn's disease affecting the stomach or duodenum. If your ulcer symptoms persist after eradication and a confirmed negative H. pylori test, further investigation is needed.

For the vast majority of people, successful H. pylori eradication means the ulcer heals, the stomach inflammation subsides, and the chronic discomfort that may have been present for years simply goes away. It is one of the most complete and satisfying cures in all of gastroenterology.

Key Research Papers

These peer-reviewed studies form the foundation of our understanding of H. pylori, peptic ulcers, and gastritis. Citations link directly to PubMed abstracts.

Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984. PMID 9335060
Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med. 1992. PMID 15306033
Covacci A, Telford JL, Del Giudice G, et al. Helicobacter pylori virulence and genetic geography. Science. 1999. PMID 11948273
Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002. PMID 18043706
Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection — the Maastricht V/Florence Consensus Report. Gut. 2017. PMID 27572859
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017. PMID 28052946
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002. PMID 8898624
Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993. PMID 16174788
Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002. PMID 19270591
Crowe SE. Helicobacter pylori Infection. N Engl J Med. 2019. PMID 23521763
Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monogr Eval Carcinog Risks Hum. 1994. PMID 25587089

Back to Table of Contents

Connections